Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAB149 dose-ranging study in COPD
2004-000025-29Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Novartis. Primary endpoint: FEV1 standardized area under the curve between 22 and 24 hours post-dosing on Day 1. Started Jun 2004; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2004-000025-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000025-29.